Does the outcome justify an oral-first treatment strategy for management of pulmonary arterial hypertension?

Chest

Volumn 140, Issue 3, 2011, Pages 697-705

  Cornwell, William K ^a   McLaughlin, Vallerie V ^a   Krishnan, Sangeetha M ^a   Rubenfire, Melvyn ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; SILDENAFIL; UNIPROST;

ADULT; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; FEMALE; FUNCTIONAL STATUS; HOSPITALIZATION; HUMAN; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT REFERRAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL; WORLD HEALTH ORGANIZATION;

EID: 80052687748     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-3019     Document Type: Article

References (30)

1. McLaughlin VV, Archer SL, Badesch DB, et al American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 Expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-1619.
2. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension . Circulation. 2006;114(13):1417-1431. (Pubitemid 44454562)
3. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16):1655-1665.
4. Voelkel NF, Quaife RA, Leinwand LA, et al National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114(17):1883-1891. (Pubitemid 44673364)
5. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):13S-24S. (Pubitemid 38759713)
6. Badesch DB, Abman SH, Ahearn GS, et al American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1)(suppl 1):35S-62S. (Pubitemid 38932341)
7. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):56S-61S. (Pubitemid 38759718)
8. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70-75.
9. Barst RJ, Rubin LJ, Long WA, et al The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-302.
10. Rich S. The current treatment of pulmonary arterial hypertension: time to redefine success. Chest. 2006;130(4):1198-1202. (Pubitemid 44583753)
11. GalièN, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30(4):394-403.
12. Benza RL, Park MH, Keogh A, Girgis RE. Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant. 2007;26(5):437-446. (Pubitemid 46602007)
13. Galiè N, Torbicki A, Barst R, et al Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmo nary Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25(24):2243-2278.
14. Taichman DB, McGoon MD, Harhay MO, et al. Wide variation in clinicians' assessment of New York Heart Association/ World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc. 2009; 84(7):586-592.
15. McGoon M, Gutterman D, Steen V, et al American College of Chest Physicians. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidencebased clinical practice guidelines. Chest. 2004;126(suppl 1):14S-34S. (Pubitemid 38932340)
16. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-163.
17. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):40S-47S. (Pubitemid 38759716)
18. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-349.
19. Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation. 1994;89(4):1733-1744.
20. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005;60(12):1025-1030. (Pubitemid 41705471)
21. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.
22. Oudiz RJ, Widlitz A, Beckmann XJ, et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest. 2004;126(1):90-94. (Pubitemid 38943122)
23. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119-1123. (Pubitemid 32971843)
24. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346(12):896-903. (Pubitemid 34984638)
25. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension . J Am Coll Cardiol. 2004;43(12 suppl S):62S-67S. (Pubitemid 38759719)
26. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003;124(1):247-254. (Pubitemid 36851359)
27. Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):68S-72S. (Pubitemid 38759720)
28. Galiè N, Ghofrani HA, Torbicki A, et al Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-2157. (Pubitemid 41653106)
29. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27(5):589-595.
30. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25(2):244-249. (Pubitemid 40246523)